Cart
sales@molnova.com
SR10067
CAS No. 1380548-02-6
SR10067 ( —— )
Catalog No. M26464 CAS No. 1380548-02-6
SR10067 is a potent, selective and brain penetrant agonist of Rev-Erbβ(IC50 = 160 nM) and Rev-Erbα(IC50 = 170 nM) with anxiolytic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 209 | Get Quote |
|
| 10MG | 336 | Get Quote |
|
| 25MG | 566 | Get Quote |
|
| 50MG | 806 | Get Quote |
|
| 100MG | 1098 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSR10067
-
NoteResearch use only, not for human use.
-
Brief DescriptionSR10067 is a potent, selective and brain penetrant agonist of Rev-Erbβ(IC50 = 160 nM) and Rev-Erbα(IC50 = 170 nM) with anxiolytic activity.
-
DescriptionSR10067 is a potent, selective and brain penetrant agonist of Rev-Erbβ(IC50 = 160 nM) and Rev-Erbα(IC50 = 170 nM) with anxiolytic activity.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1380548-02-6
-
Formula Weight465.6
-
Molecular FormulaC31H31NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)(C)Oc1ccc(OCC2Cc3ccccc3CN2C(=O)c2cccc3ccccc23)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gupta BS, Taha M, Lee MJ. Buffers more than buffering agent: introducing a new class of stabilizers for the protein BSA. Phys Chem Chem Phys. 2015 Jan 14;17(2):1114-33.
molnova catalog
related products
-
2,3-dihydro-3,5,7-tr...
(R)-Eucomol, a flavonoid derivative, displays marginal antibacterial activity. (R)-Eucomol shows cytotoxic activity against KB and P-388 cells .
-
Pitofenone hydrochlo...
Pitofenone hydrochloride, a spasmolytic compound, inhibits the acetylcholinesterase (AChE) activity from bovine erythrocytes and from electric eel with Kis of 36 and 45 μM, respectively.
-
Oblongine
Oblongine chloride may have potential haemodynamic effects, it can cause a dose-dependent reduction of systolic and diastolic blood pressure, and that these effects are not mediated by α2-adrenergic receptor stimulation.
